Profile data is unavailable for this security.
About the company
Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. It has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The Company conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.
- Revenue in AUD (TTM)337.51k
- Net income in AUD-14.87m
- Incorporated1999
- Employees--
- LocationActinogen Medical LtdSelect HouseSE 901 L 9, 109 Pitt StreetSYDNEY 2000AustraliaAUS
- Phone+61 28964-7401
- Fax+61 28964-7588
- Websitehttps://actinogen.com.au/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Little Green Pharma Ltd | 23.24m | -3.14m | 39.23m | -- | -- | 0.4835 | 58.71 | 1.69 | -0.011 | -0.0126 | 0.0833 | 0.2689 | 0.263 | 1.13 | 12.06 | -- | -3.55 | -- | -4.01 | -- | 51.02 | -- | -13.51 | -- | 2.03 | -21.27 | 0.0667 | -- | -- | -- | -- | -- | -- | -- |
| Inoviq Ltd | 751.54k | -6.51m | 46.01m | 85.00 | -- | 2.75 | -- | 61.22 | -0.0708 | -0.0708 | 0.0082 | 0.182 | 0.0339 | 2.10 | 0.873 | -- | -29.33 | -47.68 | -32.18 | -50.76 | 95.07 | -- | -866.27 | -2,527.82 | 4.93 | -- | 0.0332 | -- | 119.59 | 153.31 | 50.71 | -- | -- | -- |
| Starpharma Holdings Ltd | 10.63m | -8.40m | 47.38m | 50.00 | -- | 1.37 | -- | 4.46 | -0.0205 | -0.0205 | 0.0259 | 0.0837 | 0.2092 | 0.282 | 2.10 | -- | -16.53 | -28.47 | -20.70 | -33.66 | 92.67 | 71.62 | -79.00 | -391.82 | 5.22 | -- | 0.0833 | -- | -14.10 | -3.22 | 3.19 | -- | 11.58 | -- |
| Cynata Therapeutics Ltd | 436.25k | -13.65m | 50.30m | 0.00 | -- | 4.10 | -- | 115.29 | -0.0873 | -0.0873 | 0.0027 | 0.0683 | 0.0257 | -- | 4.26 | -- | -80.33 | -38.07 | -87.15 | -41.10 | -- | -- | -3,127.93 | -513.73 | -- | -- | 0.00 | -- | -94.96 | 19.81 | -162.20 | -- | -- | -- |
| Biotron Ltd | 1.65m | -4.02m | 51.43m | 4.00 | -- | 27.51 | -- | 31.26 | -0.0045 | -0.0045 | 0.0018 | 0.0021 | 0.3587 | -- | -- | -- | -87.73 | -64.30 | -103.46 | -74.43 | -156.30 | -108.03 | -244.54 | -231.62 | -- | -- | 0.0148 | -- | -8.16 | -2.48 | -25.59 | -- | -- | -- |
| Anteotech Ltd | 526.75k | -11.46m | 54.21m | 40.00 | -- | 10.17 | -- | 102.92 | -0.0056 | -0.0056 | 0.0003 | 0.0022 | 0.0552 | -- | 2.62 | -- | -120.11 | -68.55 | -145.22 | -75.44 | -- | -- | -2,176.15 | -1,432.10 | -- | -- | 0.1729 | -- | -46.65 | 11.41 | -18.08 | -- | 25.84 | -- |
| Vitura Health Ltd | 119.67m | 9.40m | 60.47m | 121.00 | 6.38 | 1.54 | 15.99 | 0.5053 | 0.0165 | 0.0165 | 0.2099 | 0.0681 | 1.98 | 11.22 | 10.51 | 989,034.20 | 15.25 | 15.29 | 22.30 | 21.06 | 31.23 | -- | 7.70 | 6.92 | 1.18 | 5,598.19 | 0.2359 | -- | 75.16 | -- | 128.31 | 146.95 | 54.86 | -- |
| Percheron Therapeutics Ltd | 624.51k | -10.85m | 66.71m | 8.00 | -- | 4.06 | -- | 106.83 | -0.0157 | -0.0157 | 0.0009 | 0.0182 | 0.0328 | -- | 0.3224 | -- | -56.94 | -72.09 | -66.58 | -81.73 | -- | -- | -1,737.37 | -6,558.90 | -- | -- | 0.001 | -- | 1,026.16 | 72.03 | -95.81 | -- | -- | -- |
| Biome Australia Ltd | 10.24m | -2.86m | 68.10m | 30.00 | -- | 31.59 | -- | 6.65 | -0.0141 | -0.0141 | 0.0506 | 0.0101 | 1.37 | 1.93 | 6.04 | 341,434.70 | -38.27 | -- | -74.60 | -- | 61.29 | -- | -27.97 | -- | 0.9514 | -15.92 | 0.4032 | -- | 73.58 | -- | 32.20 | -- | -- | -- |
| Actinogen Medical Ltd | 337.51k | -14.87m | 72.42m | -- | -- | 5.27 | -- | 214.56 | -0.0073 | -0.0073 | 0.0002 | 0.0051 | 0.0211 | -- | 0.7341 | -- | -92.99 | -45.55 | -105.88 | -48.24 | -- | -- | -4,405.86 | -5,369.76 | -- | -294.93 | 0.0037 | -- | 792.74 | 31.88 | -13.21 | -- | 166.95 | -- |
| PharmAust Limited | 1.85m | -7.79m | 73.24m | 52.00 | -- | 9.27 | -- | 39.57 | -0.0236 | -0.0201 | 0.0055 | 0.02 | 0.1977 | -- | 6.71 | -- | -83.26 | -25.56 | -96.46 | -28.78 | 20.06 | 90.73 | -421.04 | -59.16 | -- | -104.65 | 0.00 | -- | -13.53 | 3.42 | -263.63 | -- | -47.47 | -- |
| Orthocell Ltd | 6.06m | -7.42m | 80.59m | -- | -- | 35.22 | -- | 13.31 | -0.0369 | -0.0369 | 0.0301 | 0.0109 | 0.2182 | 1.50 | 27.68 | -- | -26.73 | -32.67 | -31.96 | -38.53 | 77.11 | 63.04 | -122.55 | -374.46 | 4.36 | -- | 0.2586 | -- | 215.24 | 51.53 | 31.39 | -- | 11.07 | -- |
| Argenica Therapeutics Ltd | 92.21k | -4.67m | 82.90m | -- | -- | 10.15 | -- | 899.06 | -0.0511 | -0.0511 | 0.001 | 0.0665 | 0.0109 | -- | 0.6384 | -- | -55.31 | -- | -69.00 | -- | -- | -- | -5,067.62 | -- | -- | -6,663.20 | 0.00 | -- | 2,340.00 | -- | -17.71 | -- | -- | -- |
| Next Science Ltd | 33.14m | -24.31m | 97.72m | -- | -- | 5.10 | -- | 2.95 | -0.1051 | -0.1051 | 0.1416 | 0.0657 | 1.46 | 7.47 | 8.33 | -- | -107.19 | -74.40 | -136.06 | -90.31 | 73.20 | 76.98 | -73.36 | -128.26 | 3.45 | -50.37 | 0.0698 | -- | 89.36 | 50.80 | -28.29 | -- | -2.28 | -- |
| Paradigm Biopharmaceuticals Ltd | 8.67m | -69.00m | 97.94m | -- | -- | 2.91 | -- | 11.30 | -0.2296 | -0.2296 | 0.0288 | 0.0962 | 0.1298 | -- | 2.25 | -- | -103.34 | -40.96 | -127.58 | -44.13 | 99.87 | -- | -796.30 | -466.85 | -- | -348.76 | 0.0085 | -- | 7.58 | 25.42 | -32.26 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Actinogen Medical Ltd's reporting currency: Australian Dollar AUD
10.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 15 Sep 2023 | 247.33m | 10.61% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 10.96k | 0.00% |
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
